<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00093522</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000389145</org_study_id>
    <secondary_id>STLMC-IMM-03-05</secondary_id>
    <secondary_id>STLMC-L-03-138</secondary_id>
    <nct_id>NCT00093522</nct_id>
  </id_info>
  <brief_title>Vaccine Therapy With or Without Fludarabine in Treating Patients With Stage IV Kidney Cancer</brief_title>
  <official_title>A Phase II Pilot Study of Tumor-Loaded Dendritic Cells Alone or Following a Non-Myeloablative Conditioning Regimen in Patients With Metastatic Renal Cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Luke's Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Vaccines made from a person's tumor cells and white blood cells may make the body&#xD;
      build an immune response to kill tumor cells. Drugs used in chemotherapy, such as&#xD;
      fludarabine, work in different ways to stop tumor cells from dividing so they stop growing or&#xD;
      die. Combining vaccine therapy with fludarabine may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: This randomized phase II trial is studying vaccine therapy and fludarabine to see&#xD;
      how well they work compared to vaccine therapy alone in treating patients with stage IV&#xD;
      kidney cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Compare the safety of vaccination comprising autologous dendritic cells loaded with&#xD;
           autologous tumor lysate and keyhole limpet hemocyanin with vs without non-myeloablative&#xD;
           fludarabine in patients with stage IV renal cell carcinoma.&#xD;
&#xD;
        -  Compare, preliminarily, the efficacy of these regimens in these patients.&#xD;
&#xD;
        -  Compare the overall survival of patients treated with these regimens.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine whether this vaccine induces tumor-reactive peripheral T-cell responses or&#xD;
           delayed-type hypersensitivity in these patients.&#xD;
&#xD;
      OUTLINE: This is a pilot, randomized study. Patients are randomized to 1 of 2 treatment arms.&#xD;
&#xD;
      All patients undergo surgery to remove tumor at metastatic sites to generate autologous tumor&#xD;
      lysate. Patients then undergo leukapheresis to obtain peripheral blood mononuclear cells for&#xD;
      the generation of dendritic cells (DC). The DC are then exposed to autologous tumor lysate&#xD;
      and keyhole limpet hemocyanin (KLH).&#xD;
&#xD;
        -  Arm I: Three weeks after leukapheresis, patients receive vaccination comprising DC&#xD;
           loaded with autologous tumor lysate and KLH (DC vaccine) intradermally once every 14&#xD;
           days for a total of 4 injections in the absence of disease progression or unacceptable&#xD;
           toxicity.&#xD;
&#xD;
        -  Arm II: Two weeks after leukapheresis, patients receive fludarabine IV over 15-30&#xD;
           minutes once daily for 3 days. Beginning approximately 5 weeks after leukapheresis,&#xD;
           patients also receive DC vaccine as in arm I.&#xD;
&#xD;
      Patients are followed at 1, 3, and 7-9 weeks, at 4, 6, 9, and 12 months, and then every 6&#xD;
      months for 2 years.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 28 patients (14 per treatment arm) will be accrued for this&#xD;
      study within 2-3 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>August 2004</start_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Safety as measured by NCI common toxicity table at completion of study</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Response as measured by RECIST guidelines and the Kaplan-Meier method at 5 years</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Survival as measured by the Kaplan-Meier method at 5 years</measure>
  </primary_outcome>
  <enrollment type="Anticipated">28</enrollment>
  <condition>Kidney Cancer</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>autologous tumor cell vaccine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>keyhole limpet hemocyanin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>therapeutic autologous dendritic cells</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fludarabine phosphate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>conventional surgery</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed renal cell carcinoma&#xD;
&#xD;
               -  Stage IV disease&#xD;
&#xD;
          -  Received no benefit from standard therapy OR ineligible for standard therapy OR&#xD;
             declined standard therapy&#xD;
&#xD;
          -  At least 1 site of metastatic disease that can be surgically removed AND at least 1&#xD;
             site of metastatic disease than can remain in the patient (indicator lesion) after&#xD;
             surgery&#xD;
&#xD;
               -  Total volume of the site or sites of disease to be surgically removed must be &gt;&#xD;
                  2.0 cm^3&#xD;
&#xD;
          -  Unidimensionally measurable disease&#xD;
&#xD;
               -  At least 20 mm by conventional techniques OR ≥ 10 mm by spiral CT scan&#xD;
&#xD;
          -  No brain metastasis&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  More than 6 months&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  WBC ≥ 3,000/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 75,000/mm^3&#xD;
&#xD;
          -  Hemoglobin ≥ 10 g/dL&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  SGPT and SGOT ≤ 2.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Bilirubin ≤ 1.5 times ULN&#xD;
&#xD;
          -  Hepatitis C antibody negative&#xD;
&#xD;
          -  Hepatitis B surface antigen negative&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine ≤ 1.5 times ULN&#xD;
&#xD;
          -  Creatinine clearance &gt; 40 mL/min&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No symptomatic congestive heart failure&#xD;
&#xD;
          -  No unstable angina pectoris&#xD;
&#xD;
          -  No cardiac arrhythmia&#xD;
&#xD;
        Immunologic&#xD;
&#xD;
          -  Coomb's test negative&#xD;
&#xD;
          -  HIV-1 and -2 negative&#xD;
&#xD;
          -  No active infection&#xD;
&#xD;
          -  No unexplained fever (temperature &gt; 100.5° F or 38.1°C)&#xD;
&#xD;
          -  No lymphocytopenia&#xD;
&#xD;
          -  No hypogammaglobulinemia&#xD;
&#xD;
          -  No autoimmune disease or other immunocompromising condition that would preclude study&#xD;
             participation&#xD;
&#xD;
          -  No history of impaired immune response&#xD;
&#xD;
          -  No history of tuberculosis OR positive PPD skin test&#xD;
&#xD;
          -  No history of allergic reaction attributed to compounds of similar biological&#xD;
             composition to study vaccine&#xD;
&#xD;
          -  No history of allergic reaction to antibiotics&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 1 month after study&#xD;
             participation&#xD;
&#xD;
          -  No psychiatric illness or social situation that would preclude study participation&#xD;
&#xD;
          -  No other malignancy within the past 5 years except resected basal cell carcinoma or&#xD;
             carcinoma in situ of the cervix&#xD;
&#xD;
          -  No other concurrent illness&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  More than 4 weeks since prior immunotherapy&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin)&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  At least 4 weeks since prior steroid therapy or steroid-containing compounds&#xD;
&#xD;
          -  At least 2 weeks since prior topical or inhaled steroids&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  More than 4 weeks since prior radiotherapy&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  More than 4 weeks since prior investigational agents&#xD;
&#xD;
          -  More than 1 week since prior antibiotics&#xD;
&#xD;
          -  No concurrent renal dialysis&#xD;
&#xD;
          -  No concurrent anticoagulants&#xD;
&#xD;
          -  No other concurrent anticancer agents or therapies&#xD;
&#xD;
          -  No other concurrent investigational agents&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John P. Hanson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Luke's Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Midwest Heart Surgery Institute, Limited</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vince Lombardi Cancer Clinic at Aurora St. Luke's Medical Center</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2007</verification_date>
  <study_first_submitted>October 6, 2004</study_first_submitted>
  <study_first_submitted_qc>October 7, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 8, 2004</study_first_posted>
  <last_update_submitted>December 18, 2013</last_update_submitted>
  <last_update_submitted_qc>December 18, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 19, 2013</last_update_posted>
  <keyword>recurrent renal cell cancer</keyword>
  <keyword>stage IV renal cell cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Keyhole-limpet hemocyanin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

